newsfilter
← Latest News
GlobeNewswire·

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease